Clinical DevelopmentDescartes-08's early clinical data indicates a deeper and more durable response compared to competitors, with a favorable safety profile.
Market PotentialCartesian's lead asset, Descartes-08, could be a first-in-class opportunity in the $1B MG market and has a differentiated role in the $1B+ SLE indication.
Regulatory MilestoneThe FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RNAC's lead development candidate, Descartes-08 for the treatment of myasthenia gravis (MG), potentially accelerating clinical development.